Why Buy Domino’s Pizza Stock?
When you think of growth stocks, you probably imagine technology…
Sell
39
HNSPF Quote, Financials, Valuation and Earnings
Last price:
$2.10
Seasonality move
:
2.73%
Day range:
$2.10 - $2.10
52-week range:
$1.50 - $5.58
Dividend yield:
2.1%
P/E ratio:
22.72x
P/S ratio:
7.52x
P/B ratio:
3.25x
Volume:
--
Avg. volume:
383
1-year change:
14.75%
Market cap:
$12.5B
Revenue:
$1.4B
EPS (TTM):
$0.11
Analysts' Opinion
-
Consensus RatingHansoh Pharmaceutical Group has received a consensus rating of --. The company's average rating is a -- based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target DownsideAccording to analysts' consensus price target of --, Hansoh Pharmaceutical Group has an estimated downside of -- from its current price of $2.10.
-
Price Target UpsideAccording to analysts, the highest upside price target is -- representing -100% upside increase from its current price of $2.10.
Fair Value
-
According to the consensus of 0 analysts, Hansoh Pharmaceutical Group has -- downside to fair value with a price target of -- per share.
HNSPF vs. S&P 500
-
Over the past 5 trading days, Hansoh Pharmaceutical Group has underperformed the S&P 500 by -12.08% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Hansoh Pharmaceutical Group does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Hansoh Pharmaceutical Group has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Hansoh Pharmaceutical Group reported revenues of --.
Earnings Growth
-
Hansoh Pharmaceutical Group has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Hansoh Pharmaceutical Group reported earnings per share of --.
Enterprise value:
9.2B
EV / Invested capital:
--
Price / LTM sales:
7.52x
EV / EBIT:
12.25x
EV / Revenue:
5.49x
PEG ratio (5yr expected):
0.40x
EV / Free cash flow:
16.06x
Price / Operating cash flow:
21.99x
Enterprise value / EBITDA:
11.41x
Gross Profit (TTM):
$1.5B
Return On Assets:
14.65%
Net Income Margin (TTM):
38.97%
Return On Equity:
18.18%
Return On Invested Capital:
16.34%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-01-06 | 2024-01-06 | 2024-01-06 | |||
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -- | -- | -- | -- | -- | |
| EBITDA | -- | -- | -- | -- | -- | |
| Diluted EPS | -- | -- | -- | -- | -- | |
| Period Ending | 2020-06-30 | 2021-06-30 | 2022-06-30 | 2023-06-30 | 2024-06-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $2.8B | $3.4B | $3.7B | $3.8B | $3.8B | |
| Total Assets | $3.1B | $4B | $4.3B | $4.4B | $4.4B | |
| Current Liabilities | $599.8M | $436.1M | $478.7M | $1B | $472.3M | |
| Total Liabilities | $628.7M | $1.1B | $1.2B | $1.1B | $518.6M | |
| Total Equity | $2.5B | $2.9B | $3.2B | $3.3B | $3.8B | |
| Total Debt | -- | $585.7M | $601.3M | $615.4M | $5.5M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-01-06 | 2024-01-06 | 2024-01-06 | |||
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -- | -- | -- | -- | |
| Cash From Investing | -- | -- | -- | -- | -- | |
| Cash From Financing | -- | -- | -- | -- | -- | |
| Free Cash Flow | -- | -- | -- | -- | -- | |
HNSPF
Sector
Market Cap
$12.5B
$49.2M
Price % of 52-Week High
37.63%
48.57%
Dividend Yield
2.1%
0%
Shareholder Yield
3.33%
-0.74%
1-Year Price Total Return
14.75%
-30.94%
Beta (5-Year)
--
0.754
Dividend yield:
2.1%
Annualized payout:
$0.02
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$2.26
200-day SMA
Buy
Level
$1.92
Bollinger Bands (100)
Buy
Level
1.66 - 2.26
Chaikin Money Flow
Buy
Level
744
20-day SMA
Sell
Level
$2.28
Relative Strength Index (RSI14)
Sell
Level
47.98
ADX Line
Sell
Level
52.34
Williams %R
Buy
Level
-94.0541
50-day SMA
Buy
Level
$2.04
MACD (12, 26)
Buy
Level
0.06
25-day Aroon Oscillator
Buy
Level
56
On Balance Volume
Neutral
Level
19.7K
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
Buy
CA Score
(Annual)
Level (1.4327)
Buy
Beneish M-Score
(Annual)
Level (-2.4702)
Buy
Momentum Score
Level (5)
Buy
Ohlson Score
Level (-3.9597)
Buy
Piotroski F Score
(Annual)
Level (5)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Hansoh Pharmaceutical Group Co Ltd is a research and development-driven pharmaceutical company in China. The company holds a broad, diversified drug portfolio in CNS diseases, oncology, anti-infectives, and diabetes. Further, it also focuses on metabolic diseases and anti-tumor. The majority of revenue is generated from the sale of pharmaceutical products in Mainland China.
Stock Forecast FAQ
In the current month, HNSPF has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The HNSPF average analyst price target in the past 3 months is --.
-
Where Will Hansoh Pharmaceutical Group Stock Be In 1 Year?
According to analysts, the consensus estimate is that Hansoh Pharmaceutical Group share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About Hansoh Pharmaceutical Group?
Analysts are divided on their view about Hansoh Pharmaceutical Group share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Hansoh Pharmaceutical Group is a Sell and believe this share price will rise from its current level to --.
-
What Is Hansoh Pharmaceutical Group's Price Target?
The price target for Hansoh Pharmaceutical Group over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is HNSPF A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Hansoh Pharmaceutical Group is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of HNSPF?
You can purchase shares of Hansoh Pharmaceutical Group via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Hansoh Pharmaceutical Group shares.
-
What Is The Hansoh Pharmaceutical Group Share Price Today?
Hansoh Pharmaceutical Group was last trading at $2.10 per share. This represents the most recent stock quote for Hansoh Pharmaceutical Group. Yesterday, Hansoh Pharmaceutical Group closed at $2.10 per share.
-
How To Buy Hansoh Pharmaceutical Group Stock Online?
In order to purchase Hansoh Pharmaceutical Group stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
What Companies Are In The VanEck Semiconductor ETF?
There’s a lot to love about the VanEck Semiconductor ETF,…
How High Can Palantir Stock Go?
Palantir Technologies (NASDAQ:PLTR) has been one of the undisputed victors…
Stock Ideas
Buy
53
Is AAPL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 40x
Buy
56
Is NVDA Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 121x
Sell
46
Is MSFT Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 36x
Alerts
Sell
39
DOGZ alert for Jan 4
Dogness (International) [DOGZ] is down 20.52% over the past day.
Buy
66
DMRC alert for Jan 4
Digimarc [DMRC] is up 16.19% over the past day.
Sell
39
MSTR alert for Jan 4
MicroStrategy [MSTR] is up 13.33% over the past day.
